Recruitment

Recruitment Status
Recruiting
Estimated Enrollment
Same as current

Summary

Conditions
  • Esophagogastric Cancer
  • HER2 Negative
Type
Interventional
Phase
Phase 2
Design
Allocation: N/AIntervention Model: Single Group AssignmentIntervention Model Description: This is a single-arm, open-label, nonrandomized, single-institution, phase II study of nivolumab in combination with FOLFOX and regorafenib as first-line therapy in patients with metastatic esophagogastric adenocarcinoma.Masking: None (Open Label)Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Description

Not Provided

Not Provided

Tracking Information

NCT #
NCT04757363
Collaborators
  • Bayer
  • Bristol-Myers Squibb
Investigators
Principal Investigator: Yelena Janjigian, MD Memorial Sloan Kettering Cancer Center